Polycystic Ovarian Syndrome (PCOS) is a common endocrine disorder affecting people with ovaries, characterized by hormonal imbalances that can lead to irregular menstrual cycles, ovarian cysts, and metabolic issues. Companies related to Polycystic Ovarian Syndrome (PCOS) may focus on various aspects, including pharmaceuticals, diagnostics, medical devices, and wellness solutions.
Latest Polycystic Ovarian Syndrome Companies Updates:
Jan 2024
Exeltis Pharmaceuticals Received FDA Fast Track designation for their LPRI-421, a fixed-dose combination therapy for PCOS managing both hormonal imbalances and metabolic issues.Collaborated with leading research institutions to conduct Phase 3 clinical trials evaluating the efficacy and safety of LPRI-421 in diverse PCOS populations.
Myovant Sciences Announced positive Phase 2b data demonstrating the effectiveness of their MVT-859, a novel oral therapy, in improving menstrual regularity and reducing hirsutism in PCOS patients.Partnered with patient advocacy groups to raise awareness about PCOS and advocate for improved research funding and access to treatment options.
Addex Therapeutics Received positive Phase 2a data suggesting their oral drug candidate, ADX7114, could potentially improve insulin sensitivity and metabolic markers in PCOS patients.Continued preclinical development of their orally active GnRH antagonist, ADX12118, for managing hormonal imbalances in PCOS.
Evotec SE (Germany) and Bayer AG (Germany)Expanded their partnership in women's health indications with a new five-year, multi-target collaboration with Celmatix Inc. to develop multiple clinical candidates for PCOS treatment.Focused on identifying and validating novel drug targets and exploring innovative therapeutic approaches for managing PCOS symptoms.
List of Polycystic Ovarian Syndrome Key companies in the market
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)